Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 4/20 | 0.53 |
| ▸ | XIAP | P98170 | 12/20 | 0.46 |
| ▸ | MME | P08473 | 3/20 | 0.44 |
| ▸ | ACE | P12821 | 3/20 | 0.44 |
| ▸ | METAP2 | P50579 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12345867 | 1.00 | METAP1 (0.53) | METAP1XIAPMMEACEMETAP2 | |
| SCHEMBL2238221 | 1.00 | METAP1 (0.53) | METAP1XIAPMMEACEMETAP2 | |
| SCHEMBL2233285 | 0.92 | METAP1 (0.54) | METAP1XIAPMMEACEMETAP2 | |
| SCHEMBL12345865 | 0.92 | METAP1 (0.54) | METAP1XIAPMMEACEMETAP2 | |
| SCHEMBL2233277 | 0.92 | METAP1 (0.54) | METAP1XIAPMMEACEMETAP2 | |
| SCHEMBL2238218 | 0.90 | METAP1 (0.53) | METAP1XIAPMMEACEMETAP2 | |
| SCHEMBL12345871 | 0.90 | METAP1 (0.53) | METAP1XIAPMMEACEMETAP2 | |
| SCHEMBL2238209 | 0.90 | METAP1 (0.53) | METAP1XIAPMMEACEMETAP2 | |
| SCHEMBL2233464 | 0.88 | METAP1 (0.57) | METAP1METAP2 | |
| SCHEMBL2233456 | 0.88 | METAP1 (0.57) | METAP1METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994161-B2 | Derivatives of 2-alkoxy-3,4,5-trihydroxy-alkyl amides, preparation and use thereof, and compositions containing the same | SANOFI-AVENTIS (FR) | 2011-08-09 | — | — | US | claimed |
| US-20090075971-A1 | DERIVATIVES OF 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYL AMIDES, PREPARATION AND USE THEREOF, AND COMPOSITIONS CONTAINING THE SAME | SANOFI-AVENTIS (FR) | 2009-03-19 | — | — | US | claimed |
| US-7994161-B2 | Derivatives of 2-alkoxy-3,4,5-trihydroxy-alkyl amides, preparation and use thereof, and compositions containing the same | SANOFI-AVENTIS (FR) | 2011-08-09 | — | — | US | disclosed |
| US-20090075971-A1 | DERIVATIVES OF 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYL AMIDES, PREPARATION AND USE THEREOF, AND COMPOSITIONS CONTAINING THE SAME | SANOFI-AVENTIS (FR) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075971-A1 | DERIVATIVES OF 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYL AMIDES, PREPARATION AND USE THEREOF, AND COMPOSITIONS CONTAINING THE SAME | CYP4B1, AADAC, ALKBH3 | METAP1 2962/4885XIAP 2970/4885MME 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.